$150 off for new clients: Use code MHA150.
$150 off for new clients with MHA150
$100 off for returning clients: Use code MHA100.
$100 off for returning clients with MHA100
Ready for your transformation? See if you’re a Mindbloom candidate.

Your Complete Guide to Psychedelic Therapy

section 01

Introduction

Psychedelic therapy is entering a renaissance period. A time of renewed interest, scientific vigor, and newfound potential to help and assist those in need of health and healing. 

Research and clinical studies being done on psychedelic medicines and therapeutic modalities are reaffirming and demonstrating the safety, efficacy, and profound potential of these healing experiences. When administered safely and properly, psychedelic medicines help treat a range of physical and mental health conditions.

But what exactly is meant by "psychedelic therapy?" What do the experiences look like? How are they done properly according to current science and collective understanding? This resource will provide some much needed clarity around the key mechanisms and protocols of psychedelic therapy, taking a look at its profile to date, what science is currently underway, and where psychedelic therapy is heading.

With a number of different experiences, practitioners, and modes of administration, the world of psychedelic therapy is nuanced. Understanding these nuances is of the utmost importance to help further collective understanding on how to best serve the communities that benefit from these experiences, and how to truly unlock the healing potential granted by psychedelic compounds, the associated experiences, and the wealth and wisdom of the practitioners who facilitate and administrate them.

History of Psychedelic Therapy

The history of psychedelic therapy begins in the 1950’s, with the original coining of the term by Canadian psychiatric researchers, including pioneer Humphrey Osmond. Much like our earlier definition, it involved the application of a single high-dose of a psychedelic after a series of psychotherapeutic preparation sessions in the treatment of substance abuse disorders, largely related to alcohol in the early days.

Throughout the 40’s and 50’s a number of psychedelic compounds were being synthesized, or introduced in larger scales to the scientific and “psychonautic” communities. As these were introduced, a series of clinical and scientific study trials inevitably followed. The potential and promise of these substances was not ignored by the academic community in any way. 
Despite the closing off of access and study in the 60’s and 70’s, psychedelic therapy and the potential of psychedelic compounds were favorably received and welcomed by the clinical and scientific community in the early days. Some researchers, such as psychedelic psychotherapeutic legend Stanislov Grof, came out with the statement: 

“In one of my early books I suggested that the potential significance of LSD and other psychedelics for psychiatry and psychology was comparable to the value the microscope has for biology or the telescope has for astronomy.” 

In other words, an important tool with the potential to significantly accelerate and move the entire psychiatric and psychedelic field forward.

Studies began and were completed across a variety of fields and factors: everything from addiction recovery, treating depression/anxiety, inducing mystical experiences, managing substance abuse, and mitigating end-of-life anxiety. Numerous sanctioned studies were done across the globe during these decades. In the process, a number of best practices, protocols, and programs were developed to help systematize and contain what has the potential to be an intense or provocative experience for the client. These studies are the birthplace of “Set & Setting”, a hallmark concept in psychedelic therapy today.

LSD was a focal point for many studies across North America and Europe during this time. This compound was a major focus, given the potency, the ability to synthesize easily in a controlled environment, and the reliability of the method of administration. It also proliferated into the public through illicit channels and became a central piece in the countercultural movements throughout the 60’s, influencing many major figures, and creating ripples in cultural consciousness that would last for decades to come.

After these ripples came large-scale lockdowns and bans against psychedelic compounds and associated research and studies. Alongside this “war on drugs” came sweeping laws and regulations preventing the access, possession, and study of these compounds. The scientific and clinical communities working in psychedelic therapy would enter a dark period for research that would last for over two decades across the majority of the world.

Then, beginning with Dr. Rick Strassman’s work to investigate the effects of N,N–DMT (DMT) in the 1990’s, the academic and scientific communities have increasingly been able to work more and more with these compounds and experiences in controlled studies with FDA oversight. Many have coined this period, leading up to the present day, a “psychedelic renaissance.” Researchers and organizations were able to pick up where the research left off, and continue exploring the profound potential of psychedelic compounds and therapies in service of helping and healing those who are in need of it.

At present, there are many funded studies underway across private organizations, research institutes, and universities. These institutions are looking at a variety of conditions —such as depression, anxiety, and PTSD— and finding the compounds, protocols, dosages, and experiences that will help alleviate their symptoms. 

Funding and public attention is flowing into the space faster than ever before, more favorable legal and regulatory environments are taking shape, and the momentum for increasing access and awareness is gaining momentum.

section 02

Definition of Psychedelic Therapy

At its core, psychedelic therapy is a combination of therapeutic techniques with experiences through psychedelic compounds. These psychedelic compounds induce novel states of consciousness and emotion that assist and augment the therapeutic “containers” they are experienced within. 

Let’s begin by looking at the two core terms involved: psychedelic, and therapy.

Defining "Psychedelic"

Psychedelic refers to a specific class of compounds that are proven to reliably and effectively induce certain non ordinary states of consciousness. There are classic characteristics of a psychedelic experience, including experiences and/or states such as: 

  • Richness of phenomenological experience
  • An experience of selflessness or altered experience of Self
  • Timelessness, or a distorted/altered sense of linear time 
  • New or novel ways of thinking/feeling 
  • A feeling of unity or connectedness to others and to the world

Each individual’s experience will vary. Some, all, or none of these experiences may happen in an individual psychedelic therapy session. These are generally accepted as notable characteristics of the psychedelic experience and the compounds that reliably induce some or all of these states.

Defining "Therapy"

Psychedelic “therapy” draws largely on the frameworks of traditional or classic therapy programs and protocols such as psychotherapy, talk therapy, cognitive-behavioral therapy, and similar modalities.

Traditionally a client will enroll with a licensed practitioner and move through a series of sessions with the aim of unpacking, understanding, and healing any unresolved traumas or conditions. 

Outside of working with a licensed therapist, there are other examples of “therapeutic experiences” which can provide similar experiences of personal healing and wholeness. One example is Somatic Experience techniques. This, and other novel conversational modalities, can be extended to specific experiences or programs that help individuals work through specific areas of themselves and their lives.

In combining psychedelics and therapeutic frameworks together, we can begin to see a larger picture of what psychedelic therapy currently is, and what it can become. By combining the rich experiences that psychedelic compounds provide —allowing safe access to novel experiences, feelings, and states of consciousness— with the rigor, expertise, and structure of therapeutic programs and protocols, a synergistic realm of healing opens up. This combination has been demonstrated to help previously treatment-resistant cases, and to accelerate and augment the progress and promise of existing therapeutic experiences.

section 03

Psychedelic Therapy Modalities

There are a number of different psychedelic therapy modalities, including but not limited to: psychedelic-assisted psychotherapy, psychedelic therapy experiences and programs, and individualized psychedelic use with the intention of returning to healing, health, and wholeness.

Though all of these terms do involve the aforementioned combination of a psychedelic compound and a therapeutic structure, the specifics of administration —dosing, frequency of experience, practitioners involved, and supporting variables— vary between each of them.

Psychedelic-Assisted Psychotherapy

Refers specifically to the use of a psychedelic compound either immediately preceding, or during, a classic psychotherapy talk session with a licensed therapist.

Through the emotional opening and novel states of consciousness provided by the compound and experience, practitioners and clients are often able to reach new depths in understanding, or cover ground that may have taken longer to arrive at in traditional talk therapy, or that was previously inaccessible to the client.

Psychedelic Therapy Programs 

Whether through different therapeutic experiences such as at-home sessions, curated and personalized programming, or orchestrated by the recommendation of an experienced practitioner, psychedelic therapy programs are similar to psychedelic-assisted psychotherapy.

They do not include psychotherapy sessions specifically, and may not involve a licensed psychotherapist. There is often supporting integration work to help understand the experience, it is an important distinction to make that these programs and protocols do not involve licensed psychotherapists.

Individual Psychedelic Therapy Experiences 

These can take the form of healing retreats, personal or recreational individual undertakings, or participation in ongoing clinical research studies. This is a category of experiences that may include only individual sessions, exist outside of a clinical environment, or be part of an on-going study to research and validate safety or efficacy profiles for new compounds or techniques that are actively being researched.

If you are considering embarking on a psychedelic therapy program, it is important to know what you are signing up for, the scope and support involved, and to be clear on your own intentions and capacities for the experience. The more clear you are on what is involved, the more personalized the programs become, and the greater potential you have to achieve the results and healing that you wish to experience.

section 04

Safety of Psychedelic Therapy

On the whole, psychedelic compounds are noted to be safe, both to the individual and the societies that they are taken within.

A bar chart showing how harmful alcohol, drugs, and substances are. Alcohol is most harmful, with classic psychedelics at the bottom of the list.

Published by the Lancet, a pioneering journal in the UK, both LSD and psilocybin come in as some of the lowest risk endogenous compounds commonly consumed in modern society. When compared to tobacco/nicotine, alcohol, and caffeine, classic psychedelic compounds have a remarkable safety profile for the individual ingesting them for the experience.

That is not to say that these are panaceas or can be taken by just about anyone. On the contrary, some compounds do have a powerful body load, or direct impact on the body's natural systems, to contend with. As is the nature of psychedelics, these are extremely potent compounds for the psyche to handle, and must be taken with care and respect to avoid doing more harm than good for the client. 

Beyond the general safety profile, the biggest mark and way to ensure client and practitioner safety in psychedelic therapy is honoring and respecting the contraindications of the particular medicine or compound. Contraindications are physical or mental indicators that mean this medicine is not appropriate for the individual. 

Each medicine and compound will come with its own list of specific contraindications, so it is important to review these, and to be honest with the practitioner during the intake/screening process. 

  • Personal medical history of heart problems
  • Personal history of high/low blood pressure
  • Personal history of brain or eye pressure
  • Family/personal history of manic or psychotic episodes
  • Actively working with major/significant depression, suicidal ideation, bipolar disorder, schizophrenia
  • Active use of SSRI, MAOI, or other pharmaceutical medications (compound specific)

This list is by no means exhaustive, and does not address specific contraindications for particular compounds, but can provide a general overview as there is a body load from psychedelic compounds (heart rate, blood pressure), and a psychic load from the psychedelic experience. These compounds temporarily alter neurochemistry, so one must be very careful when they are actively taking other medications that work on similar pathways or with similar neurotransmitters.

When taken within a safe and conducive environment with trained and licensed practitioners, psychedelic compounds and psychedelic therapies can be physically and psychically safe.

This is also an entire field of ongoing study, and the first stage of testing for public approval through the FDA — looking at the safety, dosages, quality, and best methods of administration for certain compounds and experiences. As more research is done, these safety precautions and knowledge will expand, continuing to further the efficacy of treatments and ensure the safety of clients and practitioners.

section 05

Legality of Psychedelic Therapy

Around the world, the legal environment for psychedelic therapy is starting to open up after widespread bans across the public and private sectors for the past few decades. Fortunately, legal access is emerging for both clients who wish to work with psychedelic therapies personally, and for academics and researchers who wish to use these compounds for studies to expand the scope of scientific knowledge around these medicines and experiences.

Currently, ketamine treatment is the only legal, clinician-prescribed psychedelic therapy option available to the public. 
There are legal avenues to work with other compounds in the context of clinical research studies, but there are nuances to research studies that you should be aware of before signing up.

As for the academic and research worlds, legal access has been steadily opening up for study of the compounds themselves, and to conduct clinical research trials for their safety and efficacy in the treatment of different conditions or ailments.

All of the “classic” psychedelic compounds —psilocybin (Mushrooms), LSD, and MDMA for example— currently are labelled as Schedule 1 Controlled Substances by the DEA, meaning they have no currently accepted medical value and a lack of accepted safety for use under medical supervision. Other compounds with psychedelic properties are available for licensed practitioners to prescribe only, as is the case with ketamine. 
There are organizations like MAPS (Multidisciplinary Association for Psychedelic Studies), who are pushing towards the reclassification, decriminalization, or legalization for medical use of these different compounds. A number of these compounds are moving through the FDA approval process now, and more on this is covered below in the “Compounds” section.

In the United States, there are local initiatives underway pushing psychedelic legalization movements forward, as well. The recent decriminalization of psilocybin in Denver, CO, as well as Oregon state, and the decriminalization of all entheogenic plants in Oakland, CA, are significant first dominoes to fall in the movement towards increasing accessibility and awareness of the potential of psychedelic compounds and psychedelic therapy programs.

section 06

What’s Involved in a Psychedelic Therapy Protocol?

Given the different modalities and methods of psychedelic therapy, whether that be psychedelic-assisted psychotherapy, or individual psychedelic therapy sessions, the exact programs and protocols may vary considerably.

It would be a disservice to present a single, unified picture of a psychedelic therapy protocol, though that does not mean that these programs and protocols do not follow a broad experiential arc from beginning to end. It is this experiential arc that will be explored and outlined below.

Intake/Eligibility

Any psychedelic therapy program or experience will begin with an intake and eligibility process.

There are a number of contraindications for each compound, as well as eligibility criteria on top of this. This is to ensure the safety of the client and that they are receiving the right treatment for their specific area of focus.

These initial meetings and conversations will be done with a licensed practitioner who will review medical history, discuss intentions and aims, and help provide an overview of the experience and the specific program that the client would be embarking on. If a fit is determined by the clinician, the individual can sign up for the program and begin moving through the experience.

Each individual’s experience will vary. Some, all, or none of these experiences may happen in an individual psychedelic therapy session. These are generally accepted as notable characteristics of the psychedelic experience and the compounds that reliably induce some or all of these states.

Preparation

A core component of a beneficial psychedelic therapy session and program is the preparation. Psychedelic therapy is not a magic pill, it requires a level of energetic investment from the client as well as the practitioner to ensure safety, comfort, and positive short and long-term outcomes as part of these powerful experiences. Preparation can include:

  • Richness of phenomenological experience
  • An experience of selflessness or altered experience of Self
  • Timelessness, or a distorted/altered sense of linear time 
  • New or novel ways of thinking/feeling 
  • A feeling of unity or connectedness to others and to the world

Sessions

Depending on the scope of the psychedelic therapy protocol the client is embarking on, the sessions can be anywhere from a single experience to several sessions spaced out over a number of weeks. 

This is dependent on: 

  • The individual
  • The medicine being used
  • Aims of the program
  • Specifics of the protocol/program
  • Clinician’s discretion

Each session involves preparation, the experience itself, and integration. Integration can be done individually, with a Guide or support, or with the practitioner/clinician themselves. 

Again, this is dependent on the specific program and will vary based on the individual.

Integration

Integration is the process of beginning to explore the insights, experiences, or feelings that arose during the session, and determining how to bring those lessons back into day-to-day life. This is done in the service of personal healing, transformation, and growth. 

There will be space for integration after each session, but also at the end of the program’s final session, to begin integrating the entire experience and program as a whole.

Clinical Check-In

Once the client has arrived at the end of the final session or integration phase, it is highly contextual to the individual as to what happens next. 

Working with the clinician, the client can determine the next appropriate course of action, which is often one of the following:

  • Continuing on with a new program/treatment 
  • Embarking on a different healing modality such as talk therapy to assist with the integration process
  • If the psychedelic therapy protocol feels complete, and they return to life potentially healed or renewed 

As this is highly dependent on the individual, their results during the course of treatment, their intentions for the program, and the discretion of the clinician, this step will look different for each individual.

This is a high-level overview of a classic psychedelic therapy program. As new science is introduced, new best practices are established, and this experiential arc continues to evolve and adapt. It also leaves room for personalization, as some individuals may require or want additional integration in-between sessions, for example.

Much like traditional therapeutic contexts, the exact shape and scope of the program will depend on what the practitioner and the client agree upon together, but this provides a generalized insight into an experience with psychedelic therapy in safe and legal contexts.

section 07

Neuroscience of Psychedelic Therapy

The neuroscience of psychedelic therapy —what is actually going on in the brain during a psychedelic therapy session— is one of the most actively researched and exciting fields in psychedelic science today. 
Some of the fundamental mechanisms are known, but this is still largely an ongoing area of exploration as scientists and academics continue to further our understanding of psychology, biology, phenomenology, neurology, and consciousness itself. The vast expanse of the psychedelic experience touches on all of these major areas, and though science has explored many channels in the caverns of consciousness, there are still areas waiting to be explored and understood.

The first distinction to make is that not all psychedelics work on the same areas of the brain, though many do. 
Ketamine, for example, works on the glutamate system, separate from the serotonergic pathways of other psychedelic compounds. To explore the neuroscience of ketamine further, check out our resource here
Many psychedelics, including LSD, psilocybin, and mescaline, work on the 5HT2 receptors of the serotonin systems. By selectively binding to these receptor sites, they increase the amount and reuptake of serotonin primarily, but also include other neurotransmitters. This induces many of the common hallmarks of the psychedelic experience. 

Default Mode Network

One of the most notable by-products of psychedelic medicine is a decrease in blood flow and overall activity from a part of the brain known as the Default Mode Network (DMN). This is a network largely responsible for normal consciousness — it’s operational when you aren’t doing very much. 
The DMN seems to be involved in maintaining the perceived boundaries of your sense of self, orientation to the progression of time, and other “self-regulating” systems that are largely responsible for the feeling of you being you. With the downregulation of this network, some of the experiences of timelessness, feelings of unity or connection with everything, and distortions in perception and feelings tend to come in.

The more research and studies that are done, the better understanding of the exact mechanisms, impacts, and effects of the psychedelic experience there will be. Continued studies on the neuroscience of psychedelic therapy will help to increase the overall safety profiles of these experiences. This helps create the best possible outcomes for clients, and determines how best to curate therapeutic experiences, and includes the considerations that need to be made.

section 08

Effects or Benefits of Psychedelic Therapy

Everyone’s experience of psychedelic therapy and the results that they see by the end of the programs will be different. They are not guaranteed and the compounds themselves are not magic pills. 
The therapeutic container that is established, the level of trust, safety, and readiness the client feels when going into the experience, and the level of preparation, intention-setting, and integration afterwards all play a significant role in driving enduring results to the program.

There are a number of subjective effects or benefits that are being studied as powerful agents for change in the world of managing mental health, which psychedelic therapy can reliably help facilitate in individuals. 

Here are some of the positive phenomenological healing effects that can come through psychedelic therapy:

  • The individual
  • The medicine being used
  • Aims of the program
  • Specifics of the protocol/program
  • Clinician’s discretion

These effects, when paired with a safe and effective therapeutic container, can provide a powerful catalyst for personal transformation and healing. 

When combined together, clients can see small and reliable progress, or sometimes have profound experiences that serve as definitive moments in their healing journeys. Part of the continued research and study into psychedelic therapy is establishing the best practices and approaches that reliably and responsibly bring about the greatest experience and outcomes for each individual.

section 09

Psychedelic Compounds

There are a number of psychedelic medicines and compounds actively moving through various stages of FDA and global approval pipelines to become validated and widely accessible treatments for individuals. 

This list is not exhaustive, and only includes compounds that can be considered classically psychedelic, given our definitions at the beginning of this article. Active studies, research, and legal approval varies between the various compounds, some are further along and being actively supported by the FDA, while others are in the very early stages of initial safety and efficacy research.

To follow along with this progress, refer to our Psychedelic Medicine Pipeline page.

Ketamine

In North America and across the world, ketamine treatment and therapy programs are the only current clinician-prescribed psychedelic medicine option available to the general public. It’s used primarily as an off-label treatment for conditions like anxiety and depression, though it’s shown promising results for conditions and scenarios such as OCD, smoking-cessation, suicidal ideation, and others. 

There are a number of ketamine therapy programs (Mindbloom included), and ketamine clinics that provide safe and legal access to ketamine treatment.

MDMA

There is some debate as to whether MDMA qualifies as a classic psychedelic, as it is often referred to more as an “empathogen” than a “psychedelic” in some circles. However, for the purposes of this resource we feel it deserves to be included. MDMA has shown promising results in the treatment of post-traumatic stress disorder (PTSD) in particular. 

With research and legal approval stewarded largely by MAPS, MDMA-assisted psychotherapy for PTSD has been given “Fast-Track” designation by the FDA, and is currently undergoing Stage 3 clinical trials. This is the final and most exhaustive testing stage before a medicine can become legally available for use by licensed practitioners.

Psilocybin

Psilocybin is the active ingredient in magic mushrooms (psilocybe cubensis), and is increasingly synthesized by scientists and organizations for research and treatment application. 

Depending on the condition the study is researching, psilocybin is currently at various stages of the FDA approval process. Some conditions such as end-of-life anxiety or depression, are in Stage 2, while other applications are being actively researched. 

Canada has recently granted groundbreaking access for end-of-life cancer patients to use psilocybin. It’s also granted access to some licensed clinicians for personal use, to better understand how to work with this experience in the service of their clients. Some conditions and potential use-cases actively being studied include: end-of-life anxiety, depression, smoking cessation, eating disorders, and generalized anxiety.

LSD

Lysergic acid diethylamide, commonly referred to as LSD, is a synthesized compound that gained notoriety in public consciousness during its mainstream prominence during the 1960’s. 

Despite the subsequent legal and scientific restrictions surrounding LSD, many of the early studies during the 1950’s and 1960’s show promise and potential of LSD to help manage and mitigate conditions such as generalized anxiety, depression, eating disorders, dissociative or personality disorders, among others. There are also early results from studies that have begun again after decades-long restrictions.

While there are studies currently being done to demonstrate the safety and efficacy of LSD, there are few initiatives currently underway to move LSD through the FDA approval process.

Ibogaine

Ibogaine is the active compound found in Iboga, a root bark from the Iboga tree native to Africa. In early studies, and through iboga clinics around the world, this compound has demonstrated promise around addiction recovery, specifically managing opiate addictions and the subsequent withdrawals that come from cessation.

It is one of the only compounds that has shown to facilitate opiate cessation with little to no adverse withdrawal effects or events. Though some clinics in Mexico and Africa have seen promising results with clients who have sought treatment for addiction recovery, there is more research to be done before this begins moving through official approval processes.

DMT

DMT has a smaller body of scientific work and surrounding research, despite its recognition as the first legally sanctioned research study conducted after the widespread research bans in the 1960’s and 1970’s. Similarly to other compounds, it has promising potential for managing and mitigating symptoms of mental health conditions such as anxiety, depression, and OCD, among others.

Collectively, psychedelic compounds are still in the early stages of researching and validating their broad range of potential use-cases and methods of administration. It is expected that more avenues and options will open up as good science continues to unfold in this space.

With new methods of synthesis and research, other lesser-known compounds —potentially as viable as the ones mentioned above— may come into the scientific view for study. These potential compounds include 2CB, MDA, and other derivatives of LSD or psilocybin.

section 10

Where Can I Find Psychedelic Therapy Treatment?

If you are interested in embarking on an experience with psychedelic therapy, there are two legal avenues you can currently take in North America and abroad: registering for a clinical trial/study, or to enroll in a ketamine therapy/treatment protocol.

For an overview to help you determine if the time is right to move forward with a psychedelic therapy program or experience, consider this resource with six guiding questions around readiness.

Clinical Trials 

We recently published an in-depth exploration to help you determine if a clinical trial is the right step for you and where to look.

At the time of publication, this is the only legal avenue you can take if you would like to work with any of the compounds listed other than ketamine.

Ketamine Programs

There are a number of options available to enroll in ketamine programs. 
The first step should be to determine which method of administration is right for you. Please consult a licensed clinician and your primary care provider before making this decision. This is for your health, safety, and overall wellness. 

Ketamine has multiple methods of administration: intravenous (IV) or intramuscular (IM) injection, intranasal spray, or sublingual tablets — Mindbloom’s method of administration. For more on these differences, consult our resource on types of ketamine administration here.

Based on your options, you may be able to find a provider in your town, or a nearby state, if you live in North America. Accessibility and availability will vary based on your country of residence. If you feel called to work with us here at Mindbloom, you can begin by confirming your candidacy through our quick assessment.

These are the current avenues available at the time of publication. As more science is completed, and more compounds approved, it is expected that far more psychedelic therapy services, programs, and outlets will be available moving forward.

section 11

The Future of Psychedelic Therapy

Despite all of the activity, potential, and research currently underway and outlined above,  we’re still in the early days of the psychedelic therapy renaissance. 

With more favorable regulatory environments, renewed academic and scientific interest in psychedelic compounds, and a growing need to return to individual healing and wholeness, the future of psychedelic therapy has a lot of open room to explore further. Given this, there are a few things one can expect to see in the future.

New Compounds Available

With a number of psychedelic compounds moving through various stages of the regulatory approval process, in the coming years and decades there will likely be more compounds and types of experiences available and accessible to the public. 

This allows more personalized programming options, allows new or previously underserved conditions to be treated with psychedelic therapy, and expands the scope and scale of the science of psychedelic therapy overall.

Refined Client Experiences 

With the onset of new science and studies, the therapeutic space will begin to refine best practices, hone in on qualifications and skill sets for practitioners, and determine ways to maximize the efficacy of psychedelic therapy programs. 

This is all in service of driving exceptional client outcomes and returning more people to health and wholeness faster, more reliably. Alongside this lives the possibility for new experiences altogether, more personalized programming options, and creation of opportunities to merge solid clinical outcomes with artful, human-centered experiences.

Personalized Healing Journeys 

All of the psychedelic compounds and therapeutic experiences come with their own unique strengths and areas of best applications. 

In the future, clients and practitioners may be able to work together to curate a truly personalized healing journey, working with the best modalities and the best compounds to drive safe, reliable results for clients that are truly life and world-changing.

These touch on but a fragment of the potential that renewed interest and study of psychedelic therapy can bring to the public moving forward. We’re excited to play a part in that journey, and walk towards a bright future together.

The Science